Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017

BOSTON--(BUSINESS WIRE)-- Centrexion, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced it will present three studies of CNTX-4975 at the American College of Rheumatology and the Association of Rheumatology Health Professionals’ (ACR/ARHP) 2017 Annual Meeting taking place from November 3 – 8 at the San Diego Convention Center in San Diego, California. The presentations include 6-month data from the Phase 2b TRIUMPH study assessing the efficacy and safety of CNTX-4975 for the treatment of moderate to severe chronic knee pain associated with osteoarthritis as well as 12-week and 6-month data from a study of CNTX-4975 for the treatment of intermetatarsal neuroma (Morton’s neuroma).

Full abstracts are available at http://acrabstracts.org. Details of the poster presentations are listed below.

Abstract Title (#1191): Efficacy and Safety of Cntx-4975 in Subjects with Moderate to Severe Osteoarthritis Knee Pain: 24-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Session Title: Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions
Session Type: ACR Poster Session B
Presentation Time: 9:00-11:00 a.m. PT, Monday, November 6
Location: Poster Hall

Abstract Title (#2225): Cntx-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects with Painful Intermetatarsal Neuroma (Morton’s Neuroma): An Open-Label, Ascending-Dose Study
Session Title: Pain – Basic and Clinical Aspects Poster
Session Type: ACR Poster Session C
Presentation Time: 9:00-11:00 a.m. PT, Tuesday, November 7
Location: Poster Hall

Abstract Title (#2226): Cntx-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects with Painful Intermetatarsal Neuroma (Morton’s Neuroma): A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Session Title: Pain – Basic and Clinical Aspects Poster
Session Type: ACR Poster Session C
Presentation Time: 9:00-11:00 a.m. PT, Tuesday, November 7
Location: Poster Hall

About CNTX-4975

CNTX-4975 is based on Centrexion’s proprietary STRATI™ technology (Synthetic TRans cApsaicin ulTra-pure Injection), a highly potent, ultrapure, synthetic form of trans-capsaicin (a medicine traditionally derived from the chili plant). CNTX-4975 is designed to be injected directly into the site of pain to provide rapid onset, large reduction and long duration of relief from moderate to severe pain without affecting touch sensibility or position sense.

CNTX-4975 works by selectively targeting the capsaicin receptor (TRPV1) to rapidly inactivate only the local pain fibers transmitting signals to the brain. With a short half-life, STRATI® is cleared from the body within 24 hours. This approach provides pain relief that can last for months until the ends of the local pain fibers regenerate, while leaving the rest of the nerve fiber functioning as normal, and without the risks of toxicities of NSAIDs and injected steroids or the side effects, including abuse and addiction, associated with opioid treatments.

About Centrexion Therapeutics

Centrexion Therapeutics, Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion patients living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. Centrexion Therapeutics has recently relocated from Baltimore, Md. to Boston, Mass.

For more information about Centrexion, visit http://www.centrexion.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171030005124/en/